INVO Bioscience, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by INVO Bioscience, Inc. (trading symbol: INVO) on March 15, 2021, reporting events occurring on March 10, 2021. The company, incorporated in Nevada, operates in the fertility technology sector, specifically focusing on the INVOcell device and in vivo vaginal incubation procedures.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or margin data. Specific financial details disclosed relate solely to a new joint venture transaction:
- Initial Funding: INVO Centers, LLC provided an initial $30,000 in funding to the new joint venture.
- Debt Instrument: A note was issued by the partner (HRCFG, LLC) to INVO for the $30,000 funding.
- Repayment Terms: The note is to be repaid from 30% of the joint venture's operating profit.
- Interest Rate: Interest accrues at 1.5%.
Material Changes
The primary material change is the entry into a Material Definitive Agreement to form a joint venture named HRCFG INVO LLC. This agreement establishes a dedicated INVO fertility clinic in Birmingham, Alabama. Key operational changes include:
- Partnership Structure: INVO Centers, LLC and HRCFG, LLC are the members of the joint venture.
- Roles: HRCFG will handle clinical practice expertise, recruitment, training, and day-to-day management. INVO Centers will provide exclusive access to the INVOcell technology, handle compliance/accreditation, and provide product documentation.
- Equity Issuance: INVO Bioscience will issue 25,000 shares of common stock to HRCFG upon the opening of the Birmingham clinic. An additional 25,000 shares will be issued for each subsequent clinic opened by the joint venture.
Guidance, Outlook, and Risks
The filing indicates a strategic expansion into the United States market through the opening of the first joint venture INVOcell clinic. Management commentary is limited to the announcement of the agreement and the press release issued on March 15, 2021. The filing notes that the shares issued to HRCFG will be based on the exemption provided by Section 4(a)(2) of the Securities Act of 1933. No specific financial guidance or risk factors beyond the standard incorporation of the full agreement text are detailed in this summary.
Investor Verification Checklist
- Verify the full text of the HRCFG INVO LLC limited liability company agreement (Exhibit 10.1) for detailed governance and exit clauses.
- Review the Note agreement (Exhibit 10.2) to understand the specific mechanics of the 30% operating profit repayment and interest accrual.
- Confirm the timeline for the opening of the Birmingham clinic to determine when the initial 25,000 shares will be issued.
- Assess the impact of the equity issuance on existing shareholder dilution as additional clinics are opened.